key: cord-0997079-59afea2e
authors: Lucien, Mentor Ali Ber; Canarie, Michael F.; Kilgore, Paul E.; Jean-Denis, Gladzdin; Fénélon, Natael; Pierre, Manise; Cerpa, Mauricio; Joseph, Gerard A.; Maki, Gina; Zervos, Marcus J.; Dely, Patrick; Boncy, Jacques; Sati, Hatim; del Rio, Ana; Ramon-Pardo, Pilar
title: Antibiotics and Antimicrobial Resistance in the COVID-19 Era
date: 2021-01-09
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.12.087
sha: ff28358ec53bc5ffad28fd8ddaa460212efdb9c9
doc_id: 997079
cord_uid: 59afea2e

The dissemination of COVID-19 around the globe was followed by an increased consumption of antibiotics. This is related to the concern for bacterial superinfection in COVID-19 patients. Identification of bacterial pathogens is challenging in low and middle income countries (LMIC) as there are no readily-available cost-effective, clinical or biologic markers that effectively discriminate between bacterial and viral infections. Fortunately, faced with the threat of COVID-19 spread, there has been a growing awareness of the importance of antimicrobial stewardship programs as well as infection prevention and control measures that could help reduce the microbial load and hence circulation of pathogens with reduction in dissemination of antimicrobial resistance. These measures should be improved particularly in developing countries. Studies need to be conducted to evaluate the worldwide evolution of antimicrobial resistance during the COVID-19 pandemic because pathogens do not respect borders. This issue takes on even greater importance in developing countries where scare data on resistance patterns and optimal conditions for infectious pathogen transmission coexist with the suboptimal treatment resources.

95% of COVID-19 patients were placed on antibiotic regimens even though a secondary bacterial infection was only found in 15% of the patients (Zhou et al. 2020a) . However, blood cultures from an English study in early 2020 were positive in 3.2 % of cases during the first 5 days of admission and beyond that, rose to 6.1%. In respiratory samples, a pathogenic bacterium could be identified in 34.8% of cases (Hughes et al. 2020) . In Iran, respiratory samples taken after 9 days of ICU admission were positive in 18 of 19 patients: Acinetobacter baumannii (90%) and two Staphylococcus aureus (10%) strains (Sharifipour et al. 2020) . It seems, therefore, that the prevalence of bacterial infections may vary depending on the country in question, and also, the time after onset of symptoms when the samples are taken. It seems clear the that decisions on antibiotic therapy must be informed by regional epidemiological trends and the specific circumstances of the patient treated.

The initial impression of high antibiotics consumption during a viral pandemic has been influenced by early reports from Wuhan, China indicating that 50% of patients who died from COVID-19 had secondary bacterial infections (Zhou et al. 2020a ). This phenomenon is consistent with reviews of autopsy series and post-mortem cultures from the 1918 influenza pandemic revealing that most victims had concurrent bacterial pneumonia (Morens, Taubenberger, and Fauci 2008) . Some preliminary findings from studies focusing on co-infections in COVID-19 patients report that the bacteria most frequently isolated from induced sputum and/or brochioalveolar lavage of COVID-19 patients are Mycoplasma pneumonia, Pseudomonas aeruginosa, and Haemophilus influenzae.

This suggest a difference in the co-infective pathogens of Covid19 patients from those commonly observed in co-infected patients with influenza (e.g. Streptococcus pneumoniae, Staphylococcus aureus, and Streptococcus pyogenes) (Lansbury et al. 2020) . Growing evidence suggests therefore, that antimicrobial stewardship measures specific for Covid-19 patients should be preferentially followed rather than reliance on existing empiric treatment guidelines for influenza patients with secondary bacterial infections.

However, in the face of this evolving pandemic, lessons can be drawn from previous severe outbreaks of coronavirus (SARS-CoV) to inform antimicrobial management of secondary coinfections in COVID-19 patients, as well as infection prevention control measure based on AMR.

For example, the term super-spreader has been used for settings like hospital, cruise ships, etc.

(i.e., for events where there is an important movement of population leading to high rates of J o u r n a l P r e -p r o o f transmission) (Cave 2020). Past SARS-CoV outbreaks have shown that hospitalized patients with bacterial co-infections can be super-spreaders of resistant bacteria, each individual possibly infecting more than 10 other people (Wi, De, and Mi,TH 2020) . In the case of COVID19, it has been demonstrated that 80% of contaminations are related to 20% of subjects. It remains unknown if SARS-CoV-2 has the same pattern as SARS-CoV in the spread of resistant bacteria (Cave 2020). Nonetheless, this is an important observation to keep in mind to reduce the risk of AMR infections and hospital transmission, particularly in LMIC where hospital infection prevention and control measures are often sub-optimal (Alp and Damani 2015) .

As in the case of most infections, the initial choice of antibiotics in COVID-19 patients is often empiric (Huang et al. 2020) . While 98% of these patients may have bilateral lung involvement on chest x-ray, only 28% of patients had enough sputum production to perform a Gram stain or culture (Huang et al. 2020 ). This scarcity of sputum production in these patients is further complicated by the fact that the identification of pathogens from sputum sample in patients with pneumonia is overall modest and yields results in only 23% of cases (Saldías Peñafiel et al. 2018) . Moreover, concerns about aerosol-generating procedures (i.e. deep airway suctioning or broncho-alveolar lavage) further limit the ability to obtain satisfactory sputum sample for bacterial identification and other microbiological studies ( Van Doremalen et al. 2020 ). However, if personal protective equipment are adequate, proscription of important diagnostics or therapeutic procedures should be reconsidered (Ağalar and Öztürk Engin 2020) .

Despite some preliminary evidence, it is still unclear if similar synergies exist between SARS-CoV-2 and specific bacterial infections, as exist with influenza (Rowe et al. 2019) . It has been shown that respiratory viral infections may alter innate immune function in affected pulmonary tissue, promoting bacterial growth: macrophage are overwhelmed by this increased burden of apoptotic cells and thus become limited in their capacity to phagocytose bacteria. (Morgan et al. 2018 ). It has also been observed that both dendritic cells and macrophage have diminished antigen presenting ability following bacterial and viral infections, which is linked to an immunosuppressive microenvironment involving T (Treg) cells and cytokine TGF-B-a form of immunoparalysis (Roquilly et al. 2017 ). In addition, the initial immune response to a viral lung J o u r n a l P r e -p r o o f infection modifies the respiratory tract microbiome which can, in turn, undermine immune defenses against infections pathogens (Hanada et al. 2018) . Other inciting mechanisms following viral illnesses include altered epithelial cells that disrupt the mucocilliary clearance and mucus thickening impairing the movement of immune cells (Manohar et al. 2020 ). In the particular setting of SARS-COV 2 infection, fluid and pus filled pulmonairy alveoli creating a nutritive environment for bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus (Manohar et al. 2020 ).

If such synergy is proven, the administration of antibiotics would be useful and understandable. In fact, treatment with an antibiotic (azithromycin) and antimalarial (hydroxychloroquine) had shown in vitro effectiveness against SARS-CoV-2 and have been used (Andreani et al. 2020 ).

However, the early promise of this combination therapy has had equivocal results in subsequent clinical studies: some of them found no beneficial effect (Magagnoli et al. 2020 ) whereas others point out that hydroxychloroquine yields a mortality reduction of mortality of 66%, rising to 71% in combination with azithromycin (Arshad et al. 2020 ). If some studies found potential cardiac toxicity of hydroxychloroquine combine with azithromycin ) others found no report of torsade de pointes, or fatal dysrhythmias and commented that clinicians seldom needed to discontinue therapy (Saleh et al. 2020) . Currently there is no definitive evidence on the clinical benefits of chloroquine or hydroxychloroquine, while there is evidence on the potential harm (Tang et al. 2020) .

Clinical trials are underway that may provide answers to the potential contribution of different therapies in the treatment of COVID-19. For example, the Solidarity Trial, an international study conducted by the WHO is based on the principle of repurposing drugs previously used for others indications: remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon ( WHO 2020c). 

If the use of antibiotics to treat nosocomial bacterial co-infection is justified by the risks of requiring invasive mechanical ventilation (Rawson, Moore, et al. 2020) , the paucity of ventilators in LMIC minimizes this risk and should therefore greatly reduce unnecessary antimicrobial use. (Losonczy et al. 2019 ). However, even as short-term peripheral venous catheters can be associated with higher rates of bloodstream infections in LMIC than HIC (Rosenthal et al. 2020 

LMIC might be more impacted by the COVID-19-associated antibiotic resistance for a number of reasons: reliance on empiric therapy due to the lack of clinical microbiology laboratory capacity; deficiencies in infection prevention and control measures, and; systemic stress making the implementation of new practices more difficult. There are a number of possible strategies to reduce excessive antimicrobial use and the resultant antibiotic resistance. The straight-forward strategy promoted by most ministries of health could limit antibiotic use: if you have fever or symptoms similar to flu, stay home, drink liquid and take paracetamol. Aside from the obvious public health benefit to this approach, such behavior could reduce antibiotic consumption, since patients seeking care for acute respiratory illnesses may receive unnecessary antibiotics in 41% of cases (Havers et al. 2018) . Rapid viral testing could also further reduce the unwarranted prescription of antibiotics in LMIC as it has been shown that those who tested positive for influenza were 50% less likely to receive antibiotics (Tillekeratne et al. 2015) . Unfortunately, in developing J o u r n a l P r e -p r o o f countries, antibiotics are often sold in the street without prescriptions, allowing people to purchase them with the intent to prevent or self-treat COVID-19 or other viral infections, leading to inappropriate use in the setting of non-bacterial infections.

As bacterial co-infection in COVID-19 patients may be less than 15% (Zhou et al. 2020b) , it would be prudent to reserve antibiotics for patients with suspected or severe COVID-19 manifestations.

Testing for COVID-19 in respiratory patients, therefore, may be an effective way to limit antibiotics use during the pandemic (Getahun et al. 2020 ). This approach is recommended by the WHO to combat the pandemic. However, this policy assumes that the country has the capacity to conduct testing and the means to enforce the isolation of infected patients.

Mass viral testing and timely screening has proven exacting even for HIC and it is even more so in LMIC ("Coronavirus Testing Labs Again Lack Key Supplies -The New York Times"). The fierce and unfair competition between LMIC and HIC for limited stocks of reagents and protective equipment has created additional disparities and barriers to implementing strategies to prevent spread, especially in LMICs ("In Scramble for Coronavirus Supplies, Rich Countries Push Poor Aside -The New York Times" n.d.). In addition, fragile healthcare infrastructure in many limited resource countries makes it difficult to apply basic preventive measures such as inpatient hospital isolation. Isolation rooms are severely limited in 41% of hospitals in LMIC, thereby creating the risk of exposure for patients without Covid-19 (Alp et al. 2011 ). In addition, the crowded home environments found in LMIC, makes any attempt to isolate infected patients at home illusory ("Tracking Improvement in the Lives of Slum Dwellers" n.d.). The inadequate resources for testing for Covid-19 and the limited capacity to isolate those infected raises the question of the practicality of adopting mass testing strategy in developing countries.

In this case, it is important to develop alternative response strategies. Aggressive screening of suspected cases, contact tracing and the creation of emergency, ad hoc isolation sites, etc. are very costly and complex undertakings requiring high levels of funding. Furthermore, contact tracing is probably more useful at the beginning of the outbreak than later and can be very difficult effectuate when there is a high number of daily community transmissions. However, these measures can be 

While the symptomology described in COVID-19 is generally overlapping with other respiratory infectious diseases, some specific symptoms/sign described can be used to support the diagnosis of . The presence of other clinical hallmarks such as fever, persistent cough, diarrhea, fatigue, abdominal pain and loss of appetite can further support this diagnosis (Menni et al. 2020) . While some common biomarkers, such as C reactive protein (CRP) and procalcitonin, have not proven helpful at discriminating between patients presenting with COVID-19 and those with additional bacterial coinfection, they provide some value in assessing disease severity, and could be useful for predicting the prognosis . Ongoing research is continuing to define the role of these tools in clinical decision-making (Rawson, Ming, et al. 2020 ) (Lansbury et al. 2020 ).

The WHO has develop a guidelines for clinical management of COVID-19 that do not endorse prescription of antibiotics to suspected or confirmed mild COVID-19 patients with low suspicion of a bacterial infection. However, for suspected or confirmed severe COVID-19, the use of empiric antimicrobials is recommended to treat all likely pathogens (WHO 2020b). Finally, even as there is not yet an optimal strategy for combating global COVID-19, providers in LMIC should try to establish and/or strengthen antimicrobial stewardship as well as infection prevention and control programs to reduce the emergence and dissemination of antimicrobial resistance (Septimus 2018 ). The kind of antimicrobial stewardship program that can work is very specific to context, but could include: education about antimicrobial resistance (AMR); development of guidelines;

infection prevention and control guidelines; contribution of an infectious disease consultant at the hospital level; intravenous to oral switch therapy; rules and regulation of antibiotic quality control; J o u r n a l P r e -p r o o f upgrade capacity of microbiological lab; development of national action plan, and; implementation of an infection prevention control program (Cox et al. 2017) . The choice of measures to enact would depend greatly on local factors, such as available human and economic resources, and infrastructure. Whatever the choice, interventions must be evaluated to demonstrate improvement and also guide further decisions. Ultimately, the choice must have an impact on the real world of people living in the resource constrained countries, because sometimes there is a gap between the development and implementation of public health policy and the actual benefits accruing to the population. Dialogue between researchers and policy-makers could help fill this gap. In this perspective, the scope of research undertaken, as well as the researchers themselves, must recognize the financial constraint and limitations in human resources, bureaucratic support and infrastructure political leader and decisions-makers in LMIC face and integrate these realities into their work and recommendations. It is also primordial to evaluate the cultural environment in which the policies are being implemented. That is why it is very important to facilitate a transparent and honest dialogue between the research, political and executive teams. (Cave 2020) Ultimately, the strategies discussed here could contribute to saving lives and reducing the economic cost of healthcare. In addition, an unanticipated but beneficial consequence of the COVID-19 pandemic is a heightened awareness about general infection prevention and control measures, such as hand hygiene, surface disinfection, and social distancing, which may help reduce the long-term dissemination of antimicrobial resistance. Finally, it is of the utmost importance in LMIC to continue to conduct studies on antimicrobial consumption and the prevalence of bacterial co-infection--susceptibility profiles whenever possible--to follow the evolution of antimicrobial resistance in these countries during the COVID-19 pandemic. The results of these studies could help to define the best strategies to use in settings with limited lab capacity in order to choose rational empiric antimicrobial therapy.

Protective Measures for Covid-19 for Healthcare Providers and Laboratory Personnel

Healthcare-Associated Infections in Intensive Care Units: Epidemiology and Infection Control in Low-to-Middle Income Countries

Infection Control Practice in Countries with Limited Resources

In Vitro Testing of Combined Hydroxychloroquine and Azithromycin on SARS-CoV-2 Shows Synergistic Effect

Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19

Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study

Coronavirus Testing Labs Again Lack Key Supplies -The New York Times

Antibiotic Stewardship in Low-and Middle-Income Countries: The Same but Different?

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1

Using Antibiotics Responsibly: Right Drug, Right Time, Right Dose, Right Duration

Tackling Antimicrobial Resistance in the COVID-19 Pandemic

Respiratory Viral Infection-Induced Microbiome Alterations and Secondary Bacterial Pneumonia

Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons

Procalcitonin Levels in COVID-19 Patients

Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China

Bacterial and Fungal Coinfection among Hospitalized Patients with COVID-19: A Retrospective Cohort Study in a UK Secondary-Care Setting

Rich Countries Push Poor Aside -The New York Times

Co-Infections in People with COVID-19: A Systematic Review and Meta-Analysis

Critical Care Capacity in Haiti: A Nationwide Cross-Sectional Survey

Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19

Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics?

Loss of Smell and Taste in Combination with Other Symptoms Is a Strong Predictor of COVID-19 Infection

Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza Preparedness

Innate Immune Cell Suppression and the Link With Secondary Lung Bacterial Pneumonia

Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database

Antimicrobial Resistance : Tackling a Crisis for the Health and Wealth of Nations

Enhanced Infection Control Interventions Reduced Catheter-Related Bloodstream Infections in the Neonatal Department of Hung Vuong Hospital

Antimicrobial Use, Drug-Resistant Infections and COVID-19

Bacterial and Fungal Co-Infection in Individuals with Coronavirus: A Rapid Review to Support

Clinical Infectious Diseases

Local Modulation of Antigen-Presenting Cell Development after Resolution of Pneumonia Induces Long-Term Susceptibility to Secondary Infections

Six-Year Multicenter Study on Short-Term Peripheral Venous Catheters-Related Bloodstream Infection Rates in 246 Intensive Units of 83 Hospitals in 52 Cities of 14 Countries of Middle East

Direct Interactions with Influenza Promote Bacterial Adherence during Respiratory Infections

Features of Community-Acquired Pneumonia in Immunocompetent Hospitalized Adults According to the Causal Agent

Antimicrobial Resistance: An Antimicrobial/Diagnostic Stewardship and Infection Prevention Approach

Evaluation of Bacterial Co-Infections of the Respiratory Tract in COVID-19 Patients Admitted to ICU

Antimicrobial Resistance in Africa: A Systematic Review

Hydroxychloroquine in Patients with Mainly Mild to Moderate Coronavirus Disease 2019: Open Label, Randomised Controlled Trial

Use of Rapid Influenza Testing to Reduce Antibiotic Prescriptions among Outpatients with Influenza-like Illness in Southern Sri Lanka

Tracking Improvement in the Lives of Slum Dwellers

Clinical Management of COVID-19

Solidarity Clinical Trial for COVID-19 Treatments

Solidarity Clinical Trial for COVID-19 Treatments

SHORT REPORT Hospitalized Patients with Bacterial Infections: A Potential Focus of SARS Transmission during an Outbreak Printed in the United Kingdom

Articles Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study

Articles Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study